Clinical Trial Update: Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder [Phase 3]

View source ↗

Summary

Phase 3 study update reporting long-term safety and effectiveness data for OROS methylphenidate hydrochloride in children with attention Deficit Hyperactivity D…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• OROS Methylphenidate HCl (methylphenidate hydrochloride (extended-release))

Snippet

Sponsor: Alza Corporation, DE, USA | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED